All data and related metadata were deposited in an appropriate public repository. The data on the study population that were obtained from the NHIRD (<http://w3.nhri.org.tw/nhird//date_01.html>) are maintained in the NHIRD (<http://nhird.nhri.org.tw/>). The NHRI is a nonprofit foundation established by the government.

Introduction {#sec005}
============

Pneumococcal pneumonia (PP) is a common disease worldwide and a major concern because of its high morbidity and mortality rates \[[@pone.0158501.ref001]\]. This disease can cause septic shock, acute respiratory failure, bacteremia, empyema, and meningitis in its acute stage \[[@pone.0158501.ref002],[@pone.0158501.ref003]\]. Severe morbidities after the acute stage have been observed. PP is associated with increased risk of stroke \[[@pone.0158501.ref004]\], acute cardiac events \[[@pone.0158501.ref005],[@pone.0158501.ref006]\], lung cancer \[[@pone.0158501.ref007]\], and end-stage renal disease \[[@pone.0158501.ref008]\].

Acute kidney injury (AKI) is a common problem in critically ill patients. AKI occurs in up to 70% of critically ill patients and has a mortality rate in this group more than twice that of similar patients without AKI \[[@pone.0158501.ref009]\]. Among the traditional causes of AKI, sepsis is the most common etiology \[[@pone.0158501.ref010]\]. A short episode of AKI may predispose the patient to permanent kidney damage. Coca et al observed an association between AKI and chronic kidney disease \[[@pone.0158501.ref011]\]. Clinicians should aggressively prevent AKI to avoid adverse outcomes.

PP can cause hemolytic-uremic syndrome in pediatric patients. The disease often results in AKI that requires emergent dialysis \[[@pone.0158501.ref012],[@pone.0158501.ref013]\]. Epidemiological studies on the relationship between PP in adults and AKI development are scant. Therefore, we conducted a nationwide population-based cohort study to investigate the association between PP and subsequent risk of AKI.

Methods {#sec006}
=======

Data Source {#sec007}
-----------

The National Health Insurance (NHI) program was established in Taiwan in March 1995, and currently has more than 23.75 million enrollees, covering more than 99% of the population. The National Health Research Institutes maintain the National Health Insurance Research Database (NHIRD), which contains all NHI claims data. To protect patient privacy, all medical records in the NHIRD are linked through a unique encrypted identifier. In this study, we used the NHIRD inpatient dataset and Registry of Beneficiaries. Diagnoses in the database are based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. The Institutional Research Ethic Committee of China Medical University (CMUH104-REC2-115) exempted this study from full review.

Study Participants {#sec008}
------------------

We used inpatient claims data to identify patients aged 20 years or more who were newly diagnosed with PP (ICD-9-CM code 481) between 2000 and 2011. The index date was defined as the date of initial PP diagnosis. We excluded patients with missing sex or date of birth data, and aged \<20 years. The comparison cohort was randomly selected from inpatient claims without the diagnosis of PP. For each patient with PP, 1 control patients without PP were randomly selected and frequency-matched according to year of hospitalization, age (every 5 y), sex, and comorbidities of cirrhosis, cancer, chronic kidney disease (CKD), diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), coronary artery disease (CAD), and stroke. The same exclusion criteria as used for the PP group were applied for the control group. All the study participants were followed until they were diagnosed with AKI (ICD-9-CM code 584), censored for loss to follow-up, withdrew from the NHI program, or until December 31, 2011.

Outcome and Comorbidities {#sec009}
-------------------------

In Taiwan, the AKI diagnosis before the year 2004 was based on diagnosis guideline at that time and use RIFLE criteria after the year 2004. These diagnostic codes in NHIRD would be obtained from hospital records and evaluated by two or more specialist to confirm the diagnostic accuracy.

The person-years of the follow-up were calculated for each patient until they were newly diagnosed with AKI, censored for loss to follow-up, withdrew from the insurance program, or until the end of 2011.

Comorbidities, namely cirrhosis (ICD-9-CM code 571.2, 571.5, 571.6), cancer (ICD-9-CM codes 140--208), CKD (ICD-9-CM code 585), diabetes (ICD-9-CM code 250), hypertension (ICD-9-CM codes 401--405), hyperlipidemia (ICD-9-CM code 272), chronic obstructive pulmonary disease (COPD; ICD-9-CM codes 491, 492, and 496), congestive heart failure (CHF; ICD-9-CM code 428), coronary artery disease (CAD; ICD-9-CM codes 410--414), and stroke (ICD-9-CM codes 430--438), were identified according to diagnosis prior to the AKI event. In addition, sepsis (ICD-9-CM codes 0389) was also added in the multivariable analysis. The severity were identified according to hospitalization of PP with continuous mechanical ventilation (high) or without continuous mechanical ventilation (low) (ICD-9 procedure code 967).

Ethics Statement {#sec010}
----------------

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115). The IRB also specifically waived the consent requirement.

Statistical Analysis {#sec011}
--------------------

The baseline distribution of demographic characteristics and comorbidities were evaluated using the chi-square test for categorical variables and *t* test for continuous variables between the PP and non-PP cohorts. We calculated the overall incidence density rates of AKI and age-, sex-, and comorbidity-specific rates of AKI (per 1000 person-y). Univariate and multivariate Cox proportion hazards regression models were used to examine the influence of PP on the risk of AKI, expressed as a hazard ratio (HR) with a 95% confidence interval (CI). The multivariate models were simultaneously adjusted for sepsis, age, sex, and comorbidities of cirrhosis, cancer, CKD, diabetes, hypertension, hyperlipidemia, COPD, CHF, CAD, and stroke. Stratified by sepsis, age, sex, comorbidity, follow-up time and the severity of PP, the relative risk of AKI development in the patients with PP, compared with the patients without PP, was also analyzed using the Cox models. The Cox model was also used to calculate the adjusted cumulative incidence of AKI for both PP and non-PP cohorts. All statistical analyses were conducted using SAS software Version 9.4 (SAS Institute, Inc., Cary, NC, USA). A 2-tailed *P* value of \< .05 was considered statistically significant.

Results {#sec012}
=======

The cohort comprised 10 069 PP cases and 10 069 non-PP controls for the period 2000--2011. In both cohorts, approximately 52.5% of the patients were more than 65 years old and 64.1% were men. The mean ages of the PP and non-PP cohorts were 62.7 ±18.5 and 62.2±18.7 years, respectively. The patients with PP and with non-PP had similar prevalence of cirrhosis, cancer, CKD, diabetes, hypertension, hyperlipidemia, COPD, CHF, CAD, and stroke (all *P*\>.05) ([Table 1](#pone.0158501.t001){ref-type="table"}). The cumulative incidence of AKI was higher for the PP cohort than for the non-PP cohort (*P* = .006) ([Fig 1](#pone.0158501.g001){ref-type="fig"}). In total, 429 patients with AKI were observed in the PP cohort, for an incidence rate of 10.5 per 1000 person-years; 542 patients with AKI were identified in the non-PP cohort, for an incidence rate of 10.5 per 1000 person-years, yielding a crude HR of 1.00 (95% CI = 0.92--1.08) ([Table 2](#pone.0158501.t002){ref-type="table"}). After adjustment for age, sex, and comorbidities, the patients with PP exhibited an increased risk of AKI compared with those without PP (adjusted HR \[aHR\] = 1.11, 95% CI = 1.03--1.19). The AKI incidence increased with age and was greater in male patients than in female patients. We also observed a significantly higher risk of AKI in the patients with cirrhosis (aHR = 2.58, 95% CI = 2.31--2.89), diabetes (aHR = 1.69, 95% CI = 1.56--1.82), hypertension (aHR = 1.23, 95% CI = 1.13--1.34), CHF (aHR = 1.56, 95% CI = 1.42--1.71), and stroke (aHR = 1.11, 95% CI = 1.03--1.21) than among those with no comorbidity.

![Kaplan-Meier survival analysis showed that the pneumococcal pneumonia group exhibited significantly higher acute kidney injury rates than the comparison group.](pone.0158501.g001){#pone.0158501.g001}

10.1371/journal.pone.0158501.t001

###### Demographic characteristics and comorbidities in cohorts with and without pneumococcal pneumonia.

![](pone.0158501.t001){#pone.0158501.t001g}

                                                  Pneumococcal pneumonia                
  ----------------------------------------------- ------------------------ ------------ ------
  **Age, year**                                                                         0.99
  ≤ 49                                            2627(26.1)               2627(26.1)   
  50--64                                          2160(21.5)               2160(21.5)   
  65--79                                          3381(33.6)               3380(33.6)   
  ≥80                                             1901(18.9)               1902(18.9)   
  Mean±SD[^†^](#t001fn002){ref-type="table-fn"}   62.2(18.7)               62.7(18.5)   0.05
  **Sex**                                                                               0.99
  Female                                          3616(35.9)               3616(35.9)   
  Male                                            6453(64.1)               6453(64.1)   
  **Comorbidity**                                                                       
  Cirrhosis                                       641(6.37)                641(6.37)    0.99
  Cancer                                          1690(16.8)               1690(16.8)   0.99
  CKD                                             156(1.55)                156(1.55)    0.99
  Diabetes                                        2613(26.0)               2613(26.0)   0.99
  Hypertension                                    4203(41.7)               4203(41.7)   0.99
  Hyperlipidemia                                  875(8.69)                875(8.69)    0.99
  COPD                                            3105(30.8)               3105(30.8)   0.99
  CHF                                             1430(14.2)               1430(14.2)   0.99
  CAD                                             2107(20.9)               2107(20.9)   0.99
  Stroke                                          2266(22.5)               2266(22.5)   0.99

Chi-Square Test

^†^: T-Test

CKD denotes chronic kidney disease

CAD denotes coronary artery disease

CHF denotes congestive heart failure

COPD denotes chronic obstructive pulmonary disease

10.1371/journal.pone.0158501.t002

###### Incidence and Hazard ratio for acute kidney injury and acute kidney injury -associated risk factor.

![](pone.0158501.t002){#pone.0158501.t002g}

  Variable                     Event   PY      Rate[^\#^](#t002fn001){ref-type="table-fn"}   Crude HR (95% CI)                                           Adjusted HR[^†^](#t002fn003){ref-type="table-fn"} (95% CI)
  ---------------------------- ------- ------- --------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------
  **Pneumococcal pneumonia**                                                                                                                             
  No                           542     51380   10.5                                          1.00                                                        1.00
  Yes                          429     40748   10.5                                          1.00(0.92, 1.08)                                            1.11(1.03,1.19)[\*\*](#t002fn005){ref-type="table-fn"}
  **Comorbidity**                                                                                                                                        
  **Cirrhosis**                                                                                                                                          
  No                           848     87139   9.73                                          1.00                                                        1.00
  Yes                          123     4990    24.7                                          2.53(2.26, 2.84)[\*\*\*](#t002fn006){ref-type="table-fn"}   2.58(2.31, 2.89)[\*\*\*](#t002fn006){ref-type="table-fn"}
  **Cancer**                                                                                                                                             
  No                           811     80110   10.2                                          1.00                                                        1.00
  Yes                          160     12019   13.3                                          1.32(1.19, 1.46)[\*\*\*](#t002fn006){ref-type="table-fn"}   0.94(0.85,1.04)
  **CKD**                                                                                                                                                
  No                           953     91122   10.5                                          1.00                                                        1.00
  Yes                          18      1007    17.9                                          1.71(1.29, 2.27)[\*\*\*](#t002fn006){ref-type="table-fn"}   0.99(0.76, 1.30)
  **Diabetes**                                                                                                                                           
  No                           554     69904   7.93                                          1.00                                                        1.00
  Yes                          417     22224   18.8                                          2.37(2.19, 2.56)[\*\*\*](#t002fn006){ref-type="table-fn"}   1.69(1.56, 1.82)[\*\*\*](#t002fn006){ref-type="table-fn"}
  **Hypertension**                                                                                                                                       
  No                           369     55249   6.68                                          1.00                                                        1.00
  Yes                          602     36880   16.3                                          2.44(2.26, 2.64)[\*\*\*](#t002fn006){ref-type="table-fn"}   1.23(1.13,1 .34)[\*\*\*](#t002fn006){ref-type="table-fn"}
  **Hyperlipidemia**                                                                                                                                     
  No                           870     83684   10.4                                          1.00                                                        1.00
  Yes                          101     8445    12.0                                          1.15(1.02, 1.30)[\*\*\*](#t002fn006){ref-type="table-fn"}   0.89(0.78, 1.01)
  **COPD**                                                                                                                                               
  No                           604     64548   9.36                                          1.00                                                        1.00
  Yes                          367     27581   13.3                                          1.42(1.31, 1.54)[\*\*\*](#t002fn006){ref-type="table-fn"}   0.94(0.87, 1.02)
  **CHF**                                                                                                                                                
  No                           703     80151   8.77                                          1.00                                                        1.00
  Yes                          268     11978   22.4                                          2.55(2.34, 2.78)[\*\*\*](#t002fn006){ref-type="table-fn"}   1.56(1.42,1 .71)[\*\*\*](#t002fn006){ref-type="table-fn"}
  **CAD**                                                                                                                                                
  No                           654     73201   8.93                                          1.00                                                        1.00
  Yes                          317     18928   16.8                                          1.8791.73, 2.03)[\*\*\*](#t002fn006){ref-type="table-fn"}   0.97(0.89, 1.06)
  **Stroke**                                                                                                                                             
  No                           642     73647   8.72                                          1.00                                                        1.00
  Yes                          329     18481   17.8                                          2.04(1.88, 2.21)[\*\*\*](#t002fn006){ref-type="table-fn"}   1.11(1.03, 1.21)[\*](#t002fn004){ref-type="table-fn"}

^\#^: incidence rate, per 1,000 person-years

Crude HR, relative hazard ratio

^†^: multivariable analysis including age, sex, and comorbidities of cirrhosis, cancer, CKD, diabetes, hypertension, hyperlipidemia, COPD, CHF, CAD, and stroke

\*p\<0.05

\*\*p\<0.01

\*\*\*p\<0.001.

The risk of AKI in the patients with PP was significantly higher than that in patients without PP for without sepsis group (aHR = 1.09, 95% CI = 1.01--1.18), with sepsis group (aHR = 1.16, 95% CI = 1.06--1.26), aged 65-79y group (aHR = 1.28, 95% CI = 1.13--1.45), and males (aHR = 1.17, 95% CI = 1.07--1.29) ([Table 3](#pone.0158501.t003){ref-type="table"}). The stratified analysis conducted according to the follow-up duration showed that the PP cohort to non-PP cohort developed the highest risk of AKI within 1 year of follow-up (aHR = 1.97, 95% CI = 1.79--2.16). Furthermore, the PP cohort with continuous mechanical ventilation exhibited a significantly much higher risk of AKI compared to the non-PP cohort (aHR = 2.09, 95% CI = 1.81--2.42) ([Table 4](#pone.0158501.t004){ref-type="table"}).

10.1371/journal.pone.0158501.t003

###### Incidence of acute kidney injury by age, sex and comorbidity and Cox model measured hazards ratio for patients with pneumococcal pneumonia compared those without pneumococcal pneumonia.

![](pone.0158501.t003){#pone.0158501.t003g}

                                                              Pneumococcal pneumonia                                                                                                   
  ----------------------------------------------------------- ------------------------ ------- ------ ----- ------- ------ ----------------------------------------------------------- -----------------------------------------------------------
  **Acute kidney injury without sepsis**                      408                      51380   7.94   320   40748   7.85   2.07(1.91, 2.25)[\*\*\*](#t003fn007){ref-type="table-fn"}   1.09(1.01, 1.18)[\*](#t003fn005){ref-type="table-fn"}
  **Acute kidney injury with sepsis**                         134                      51380   2.61   109   40748   2.67   1.96(1.78, 2.15)[\*\*\*](#t003fn007){ref-type="table-fn"}   1.16(1.06, 1.26)[\*\*](#t003fn006){ref-type="table-fn"}
  **Age, years**                                                                                                                                                                       
  ≤ 49                                                        41                       15827   2.59   38    14585   2.61   1.01(0.85, 1.20)                                            1.10(0.94, 1.29)
  50--64                                                      86                       11509   7.47   76    9612    7.91   1.06(0.89, 1.26)                                            1.09(0.92, 1.29)
  65--79                                                      236                      17147   13.8   216   12331   17.5   1.27(1.12, 1.44)[\*\*\*](#t003fn007){ref-type="table-fn"}   1.28(1.13, 1.45)[\*\*\*](#t003fn007){ref-type="table-fn"}
  ≥80                                                         179                      6897    26.0   99    4220    23.5   0.90(0.77, 1.06)                                            0.90(0.76, 1.06)
  **Sex**                                                                                                                                                                              
  Female                                                      180                      19466   9.25   127   16319   7.78   0.84(0.74, 0.96)[\*](#t003fn005){ref-type="table-fn"}       0.98(0.87, 1.11)
  Male                                                        362                      31914   11.3   302   24429   12.4   1.09(0.99, 1.20)                                            1.17(1.07, 1.29)[\*\*\*](#t003fn007){ref-type="table-fn"}
  **Comorbidity**[^**‡**^](#t003fn004){ref-type="table-fn"}                                                                                                                            
  No                                                          33                       15714   2.10   20    14454   1.38   0.66(0.38, 1.15)                                            0.77(0.44, 1.36)
  Yes                                                         509                      35667   14.3   409   26294   15.6   1.09(0.95, 1.24)                                            1.14(1.00, 1.30)
  **Follow-up time, years**                                                                                                                                                            
  ≤1                                                          85                       9460    8.98   139   8224    16.9   1.88(1.71, 2.07)[\*\*\*](#t003fn007){ref-type="table-fn"}   1.97(1.79, 2.16)[\*\*\*](#t003fn007){ref-type="table-fn"}
  2--4                                                        215                      21421   10.0   146   16815   8.68   0.87(0.70, 1.07)                                            0.96(0.78, 1.19)
  ≥5                                                          242                      20499   11.8   144   15709   9.17   0.78(0.63, 0.96)[\*](#t003fn005){ref-type="table-fn"}       0.94(0.76, 1.15)

^\#^: incidence rate, per 1,000 person-years

Crude HR, relative hazard ratio

^†^: multivariable analysis including sepsis, age, sex, and comorbidities of diabetes, hypertension, hyperlipidemia, COPD, CHF, CAD, stroke, cirrhosis, cancer, and CKD

^‡^: Patients with any one of the comorbidities diabetes, hypertension, hyperlipidemia, COPD, CHF, CAD, stroke, cirrhosis, cancer, and CKD as the comorbidity group

\*p\<0.05

\*\*p\<0.01

\*\*\*p\<0.001.

10.1371/journal.pone.0158501.t004

###### Cox Proportional Hazard Regression Analysis for the risk of acute kidney injury stratified by the severity of pneumococcal pneumonia.

![](pone.0158501.t004){#pone.0158501.t004g}

  Variables                                                                       N       Event   Rate[^\#^](#t004fn001){ref-type="table-fn"}   Adjusted HR[^†^](#t004fn002){ref-type="table-fn"} (95% CI)
  ------------------------------------------------------------------------------- ------- ------- --------------------------------------------- ------------------------------------------------------------
  **Non-pneumococcal pneumonia**                                                  10069   542     10.6                                          1(Reference)
  **Pneumococcal pneumonia severity**[^**&**^](#t004fn004){ref-type="table-fn"}                                                                 
  Without continuous mechanical ventilation(Low)                                  8650    362     9.46                                          1.02(0.94, 1.10)
  With continuous mechanical ventilation(High)                                    1419    67      27.1                                          2.09(1.81, 2.42)[\*\*\*](#t004fn003){ref-type="table-fn"}

^\#^: incidence rate, per 1,000 person-years

^†^: multivariable analysis including age, sex, and comorbidities of diabetes, hypertension, hyperlipidemia, COPD, CHF, CAD, stroke, cirrhosis, cancer, and CKD

\*\*\*P\< .001

^&^severity were identified according to hospitalization of pneumococcal pneumonia with continuous mechanical ventilation (High) or without continuous mechanical ventilation (Low).

Discussion {#sec013}
==========

AKI is an abrupt loss of renal function within a short time; sepsis is the most common etiology of the condition. *Streptococcus pneumonia* is a common etiology of pneumonia with sepsis and, in its acute stage, can increase the risk of AKI. Sepsis-mediated hypoperfusion and hypoxemia may result in peritubular hypoxia and then cause AKI \[[@pone.0158501.ref014],[@pone.0158501.ref015]\]. We observed the highest risk of AKI during the first follow-up year after PP. The stratified analysis conducted according to with or without sepsis showed that the PP cohort developed higher risk of AKI compared to non-PP cohort. This phenomenon may be explained by the growing evidence of cellular and inflammatory-mediated injury observed in addition to hypoperfusion in sepsis-associated AKI pathophysiology \[[@pone.0158501.ref016]--[@pone.0158501.ref019]\]. The surface capsular polysaccharides of pneumococcus trigger host inflammatory responses and induce the production of cytokines \[[@pone.0158501.ref020]\]. Panichi et al reported that increased levels of inflammation markers such as C-reactive protein and interleukin-6 are predictors of deteriorating renal function in elderly patients \[[@pone.0158501.ref021]\]. Ficek et al showed that tumor necrosis factor-α is a contributing factor for acute renal failure in sepsis \[[@pone.0158501.ref022]\] and induces renal interstitial fribrosis by increasing production of transforming growth factor-β1 \[[@pone.0158501.ref023]\]. Wittenhagen et al found that an increased soluble urokinase-type plasminogen activator receptor (suPAR) level reflects an increased expression of inflammatory cells in vessels during pneumococcal sepsis \[[@pone.0158501.ref024]\]. An elevated suPAR level during PP might reflect ongoing inflammation that contributes to subsequent podocyte damage, thus resulting in AKI. The findings of these studies are consistent with our epidemiological results.

In this study, the comorbidities and coexistent conditions associated with the development of AKI between the study cohort and comparison cohort were similar. PP remained an independent risk factor for developing AKI after covariates were adjusted. The AKI incidence increased with age in this study was consistent with previous report. Kidney function deteriorates with age, thus increasing AKI risk \[[@pone.0158501.ref025]\].

Our multivariable regression analysis revealed elevated AKI rates among the patients with diabetes, hypertension, congestive heart failure, cirrhosis and stroke. These results are consistent with previous studies. Furthermore, the HR of AKI was higher in the younger patients with PP than in the older ones; this is possibly because the older subgroup exhibited more comorbidities and underlying medical illnesses, which may have reduced the effect of PP on their AKI. This phenomenon was also observed in the comorbidity-stratified results.

This study has several limitations. First, the NHIRD does not contain detailed information about the current medications of the patient or hydration fluid status which are potential confounding factors that might have influenced the study outcomes. Second, the insurance claims database do not contain detailed information regarding patients with PP, including clinical factors related to the severity of the infection, such as shock, laboratory values of white blood cell count, platelet count, blood urea nitrogen and serum creatinine levels (AKI severity), all of which might be confounding factors in this study. However, we use indicator \'\'continuous mechanical ventilation\'\' as severity of PP. Third, the evidence derived from a retrospective cohort study is generally lower in statistical quality than that from randomized trials because of potential biases related to adjustments for confounding variables. Fourth, a prospective patient registration survey is required to monitor the change of estimated glomerular filtration rate in patients after PP infection.

In conclusion, the patients hospitalized for PP exhibited an increased risk of AKI compared with inpatients without PP. One episode of PP might exert clinically substantial renal effects. We recommend that physicians carefully monitor renal function when treating patients with a history of PP.

PP

:   pneumococcal pneumonia

AKI

:   acute kidney injury

aHR

:   adjusted hazard ratio

CI

:   confidence interval

NHIRD

:   National Health Insurance Research Database

BNHI

:   Bureau of National Health Insurance

NHI

:   National Health Insurance

NHIA

:   National Health Insurance Administration

NHRI

:   National Health Research Institutes

LHID 2000

:   Longitudinal Health Insurance Database 2000
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